{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:57:37Z","timestamp":1794743857878,"version":"4.9.1"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of therapeutic recombinant monoclonal antibodies (mAbs) has triggered concerns of mis-diagnosis of a plasma cell dyscrasia in treated patients. The purpose of this study is to determine if infliximab (INF), adalimumab (ADA), eculizumab (ECU), vedolizumab (VEDO), and rituximab (RITU) are detected as monoclonal proteins by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE).<\/jats:p>\n                  <jats:p>Pooled normal sera were spiked with various concentrations (ranging from trough to peak) of INF, ADA, ECU, VEDO and RITU. The peak concentration for VEDO and RITU was also added to samples with known monoclonal gammopathies. All samples were analyzed by SPEP (Helena Laboratories) and IFE (Sebia); sera containing peak concentrations of mAbs were reflexed to electrospray-time-of-flight mass spectrometry (AbSciex Triple TOF 5600) for the intact light chain monoclonal immunoglobulin rapid accurate mass measurement (miRAMM).<\/jats:p>\n                  <jats:p>For all mAbs tested, no quantifiable M-spikes were observed by SPEP at any concentration analyzed. Small \u03b3 fraction abnormalities were noted on SPEP for VEDO at 300 \u03bcg\/mL and RITU at 400 \u03bcg\/mL, with identification of small IgG \u03ba proteins on IFE. Using miRAMM for peak samples, therapeutic mAbs light chain accurate masses were identified above the polyclonal background and were distinct from endogenous monoclonal gammopathies.<\/jats:p>\n                  <jats:p>MAbs should not be easily confounded with plasma cell dyscrasias in patients undergoing therapy except when a SPEP and IFE are performed within a couple of days from infusion (peak). In ambiguous cases the use of the miRAMM technology could precisely identify the therapeutic mAb distinct from any endogenous monoclonal protein.<\/jats:p>","DOI":"10.1515\/cclm-2015-1023","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T06:48:57Z","timestamp":1453358937000},"source":"Crossref","is-referenced-by-count":51,"title":["Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation"],"prefix":"10.1515","volume":"54","author":[{"given":"Maria Alice V.","family":"Willrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Ladwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna D.","family":"Andreguetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Barnidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Katzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref121","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","year":"2008","journal-title":"Clin Pharmacol Therap"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2011.08644.x","article-title":"Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis","volume":"155","year":"2011","journal-title":"Br J Haematol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","year":"2009","journal-title":"Clin Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","year":"2008","journal-title":"Clin Pharmacol Therap"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","year":"2015","journal-title":"Methods"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1373\/clinchem.2010.152116","article-title":"Interference of monoclonal antibody therapies with serum protein electrophoresis tests","volume":"56","year":"2010","journal-title":"Clin Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","year":"2014","journal-title":"J Proteome Res"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","year":"2015","journal-title":"Methods"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","year":"2014","journal-title":"J Proteome Res"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/pr5005967","article-title":"Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry","volume":"13","year":"2014","journal-title":"J Proteome Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/pr5005967","article-title":"Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry","volume":"13","year":"2014","journal-title":"J Proteome Res"},{"key":"ref111","first-page":"e235","article-title":"Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins","volume":"52","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.intimp.2015.07.007","article-title":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS\/MS","volume":"28","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1373\/clinchem.2010.152116","article-title":"Interference of monoclonal antibody therapies with serum protein electrophoresis tests","volume":"56","year":"2010","journal-title":"Clin Chem"},{"key":"ref171","first-page":"10S","article-title":"A-260 vedolizumab quantitation in serum using SRM and micro LC-ESI-Q-TOF mass spectrometry","volume":"61","year":"2015","journal-title":"Clin Chem"},{"key":"ref51","first-page":"10S","article-title":"A-260 vedolizumab quantitation in serum using SRM and micro LC-ESI-Q-TOF mass spectrometry","volume":"61","year":"2015","journal-title":"Clin Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","year":"2009","journal-title":"Clin Chem"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2011.08644.x","article-title":"Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis","volume":"155","year":"2011","journal-title":"Br J Haematol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.intimp.2015.07.007","article-title":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS\/MS","volume":"28","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"ref231","first-page":"e235","article-title":"Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins","volume":"52","year":"2014","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T19:51:38Z","timestamp":1619034698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1023\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":24,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1023","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}